Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2011 - 2026)

Alnylam Pharmaceuticals (ALNY) has 14 years of Other Non-Current Assets data on file, last reported at $63.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 13.91% year-over-year to $63.6 million; the trailing twelve-month figure through Mar 2026 stood at $63.6 million (down 13.91% YoY), and the FY2025 full-year result was $59.5 million, down 8.96% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $63.6 million, up from $59.5 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $92.7 million in Q2 2023 and bottomed at $55.8 million in Q3 2025.
• The 5-year median for Other Non-Current Assets is $66.1 million (2022), against an average of $68.2 million.
• The widest annual swing landed in 2022, when Other Non-Current Assets surged 123.4%; it then fell 28.06% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $66.1 million in 2022, then slipped by 6.34% to $61.9 million in 2023, then gained by 5.51% to $65.3 million in 2024, then retreated by 8.96% to $59.5 million in 2025, then gained by 6.88% to $63.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $63.6 million (Q1 2026), $59.5 million (Q4 2025), and $55.8 million (Q3 2025), per Business Quant data.

Peer Comparison